Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 0.180 | 0.180 | 0.000 |
Shares | 99.820 | 99.820 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 16.278 | 16.336 |
Price to Book | 1.910 | 1.941 |
Price to Sales | 1.953 | 1.540 |
Price to Cash Flow | 12.663 | 10.054 |
Dividend Yield | 4.511 | 3.223 |
5 Years Earnings Growth | 12.036 | 12.944 |
Name | Net % | Category Average |
---|---|---|
Healthcare | 32.000 | 27.503 |
Industrials | 31.360 | 28.851 |
Financial Services | 14.770 | 17.587 |
Basic Materials | 7.470 | 5.513 |
Consumer Cyclical | 6.290 | 6.028 |
Consumer Defensive | 5.020 | 6.866 |
Utilities | 3.090 | 4.286 |
Number of long holdings: 26
Number of short holdings: 0
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
DSV | DK0060079531 | 15.83 | 1,479.0 | +0.96% | |
Novo Nordisk B | DK0062498333 | 11.78 | 581.0 | -0.10% | |
Danske Bank | DK0010274414 | 7.85 | 216.4 | +0.93% | |
Novozymes B | DK0060336014 | 7.46 | 407.8 | -0.95% | |
Coloplast | DK0060448595 | 7.08 | 816.8 | -0.44% | |
Pandora | DK0060252690 | 6.28 | 1,342.0 | +1.59% | |
Vestas Wind | DK0061539921 | 5.94 | 95.1 | +2.70% | |
Genmab | DK0010272202 | 5.56 | 1,512.0 | +0.13% | |
Carlsberg B | DK0010181759 | 3.74 | 730.2 | +0.91% | |
Oersted AS | DK0060094928 | 3.09 | 256.90 | -1.95% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
LI Aktier Globale Indeks | 6.36B | 32.42 | 11.39 | 11.31 | ||
LI Aktier Globale III | 9.67M | 16.99 | 4.07 | - | ||
LI Aktier Globale | 17.63M | 26.73 | 2.96 | 10.87 | ||
LI Aktier Globale II | 18.05M | 20.07 | 8.64 | 9.71 | ||
LI Aktier Europa | 8.81M | 20.19 | 8.52 | 9.32 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review